MedTrace Logo

Assessment and Treatment of Caffeine Dependence

NCT00338195 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2013-03-07

No results posted yet for this study

Summary

Recent research has established that some individuals report that they are unable to cease caffeine use, despite feeling that caffeine is posing a health risk or causing significant impairment in their daily activities. Despite the high rates of unsuccessful efforts to cease or control caffeine use in the population, there has been little research on the parameters of successful caffeine reduction and no research on caffeine cessation.

The goals of the study are as follows:

1. evaluate the applicability of DSM-IV dependence criteria for self-reported problematic caffeine use.
2. evaluate characteristics (e.g, co-morbid psychopathology) of individuals who report that they have had difficulty quitting caffeine use on their own and who are seeking treatment for caffeine use.
3. test the efficacy of a caffeine reduction treatment administered to individuals who would like to quit/reduce caffeine use, but have found it difficult to do so in the past.

Conditions

  • Self-identified Problematic Caffeine Use
  • DSM-IV Substance Dependence as Applied to Caffeine

Interventions

BEHAVIORAL

Individualized caffeine cessation instructions

Intervention is described in the protocol

Sponsors & Collaborators

Principal Investigators

  • Roland R Griffiths, Ph.D. · Professor, Johns Hopkins University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00338195 on ClinicalTrials.gov